Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKAPI trial of Arikayce added to multidrug therapy for Mycobacterium xenopi pulmonary infection
2023-506843-40-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amikacin in Mycobacterium xenopi infection and nontuberculous mycobacterial lung disease (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: 3-month sputum conversion rate. Planned start Oct 2025; status: authorised.
02
Drugs
amikacin
03
Conditions
Mycobacterium xenopi infectionnontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on 2023-506843-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506843-40-00.